IHS Chemical Week

EnviroTech :: Biotech

Teva to Acquire Ratiopharm for $4.9 Billion

10:46 PM MDT | March 18, 2010 | Deepti Ramesh

Teva Pharmaceutical Industries (Petah Tikva, Israel), the leading generics pharmaceutical company in the world, says it has entered into a definitive agreement to acquire Ratiopharm (Ulm, Germany), the second largest generics producer in Germany and the sixth largest generics drug company worldwide, for an enterprise value of €3.62 billion ($4.9 billion). Teva expects to complete the acquisition by the end of 2010. The acquisition will position Teva as the leading generics company in Europe, Teva says. Ratiopharm had sales of about €1.6 billion ($2.2...

This information is only available to Chemical Week subscribers.


Forgot your user ID or password?
Click here to have it sent to you.

Not an IHS Chemical Week member yet?

Here's why you should be:

  • 31 issues of Chemical Week magazine in print or digital format
  • Critical daily news and analysis on chemweek.com
  • Free mobile edition 
  • 20+ years of online archives
  • Topical e-newsletters that capture the most impactful events
  • Special issues with a regional or company focus
  • Global Outlook issue

Subscribe now

100% Satisfaction Guarantee
If at any time you are not completely satisfied with IHS Chemical Week, simply notify us and we'll refund the balance of your paid subscription - no problem.

Learn more about group subscriptions and site licenses.


contact us | about us | customer care | privacy policy | sitemap | advertise

ihsCopyright © 2015 IHS, Inc. All rights reserved. Reproduction in whole or in part without permission is prohibited.

North Asia Russia Southeast Asia China India/Pakistan Middle East Eastern Europe Western Europe Central America Canada USA Australia/New Zealand South America Africa